{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    8,
    9,
    10,
    11,
    19,
    20,
    21,
    23,
    24,
    25,
    26,
    27
  ],
  "modelUsed": "claude-opus-4-5",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "ALXN1840 15 mg followed by 30 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive ALXN1840 15 mg once daily for approximately 28 days followed by titration to 30 mg once daily starting on Day 29"
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Treatment experienced (Cohort 1)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received WD therapy for > 28 days"
      },
      {
        "id": "cohort_2",
        "name": "Treatment naïve (Cohort 2)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received WD therapy for ≤ 28 days"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 5,
      "cohortCount": 2
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Hepatology",
        "Metabolic Disorders"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": null,
      "therapeuticAreas": [
        "Hepatology",
        "Metabolic Disorders"
      ]
    },
    "arms": [
      {
        "name": "ALXN1840 15 mg followed by 30 mg",
        "type": "Experimental Arm",
        "description": "Participants receive ALXN1840 15 mg once daily for approximately 28 days followed by titration to 30 mg once daily starting on Day 29"
      }
    ],
    "cohorts": [
      {
        "name": "Treatment experienced (Cohort 1)",
        "characteristic": "Patients who have received WD therapy for > 28 days"
      },
      {
        "name": "Treatment naïve (Cohort 2)",
        "characteristic": "Patients who have received WD therapy for ≤ 28 days"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Screening period prior to enrollment"
      },
      {
        "name": "Run-in Period",
        "description": "Day -8 to Day -1: Diet equilibration (Day -7 through Day -5) and pretreatment copper/molybdenum balance measurement (Day -4 through Day -1)"
      },
      {
        "name": "Inpatient Period 1",
        "description": "Day -8 to Day 9: Includes Run-in Period and initial 15 mg/day treatment with collection period"
      },
      {
        "name": "Outpatient Period",
        "description": "Day 9 to Day 22/23: Participants discharged from CRU, may be extended up to 14 additional days"
      },
      {
        "name": "Inpatient Period 2",
        "description": "Day 23 to Day 40: 15 mg/day steady state collection (Day 25-28), titration to 30 mg/day (Day 29), and 30 mg/day accumulation and steady state collection (Day 29-39)"
      }
    ]
  }
}